Biologicals company Indian Immunologicals Limited (IIL) today inaugurated its 'New Bovine Serum' manufacturing plant in New Zealand.
The plant will produce key products like new born calf serum, adult bovine serum (NZ origin) and bulk bovine haemoglobin (NZ origin) for bio-pharmaceutical, research and diagnostic purpose, IIL said in a statement.
"At the new plant, bovine blood will be collected only from EU and USDA approved abattoirs in closed method under hygienic conditions. All the operations are subjected to daily independent verification by veterinarians employed by Ministry of Primary industries, New Zealand", it added.
In October 2014, IIL had announced of setting up a bovine serum manufacturing plant through its subsidiary Pristine Biologicals (NZ) Limited in New Zealand with an investment of USD 1 million.
"The objective of the investment was to gain control over the supplies of a key ingredient used in vaccine manufacture. Serum from New Zealand is highly regarded as the country is free from several diseases listed by the OIE. The new plant can manufacture up to 300 tonnes of serum," it added.
IIL Managing Director K V Balasubramaniam said Pristine would bring the science of bio-pharmaceuticals to the users of bovine serum and the rigour in quality assurance and management which would in turn ensure that users bring high quality to their products.
IIL, the largest seller of the foot and mouth disease vaccine, is a subsidiary of the National Dairy Development Board.
